文献速递妇科肿瘤

Avelumab治疗错配修复缺陷与错配修复完整复发/持续性子宫内膜癌的II期研究

Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer.
PubMed 文献 · J Clin Oncol · 2019-08-28

该II期研究评估PD-L1抑制剂Avelumab在子宫内膜癌两个队列中的疗效:MMRD/POLE队列和MMRP队列。MMRP队列因无效提前关闭,16例中仅1例同时达到客观缓解和6个月无进展生存;MMRD队列17例中4例客观缓解(OR率26.7%,95%CI 7.8%-55.1%),6例PFS6(40.0%,95%CI 16.3%-66.7%),且缓解不依赖PD-L1表达。结论认为Avelumab在MMRD子宫内膜癌中有 promising 活性,IHC是有效的患者筛选工具,而在MMRP/非POLE突变者中活性低。

要点

  • Avelumab在MMRD子宫内膜癌中OR率26.7%,PFS6率40.0%。
  • MMRP队列因无效提前关闭,16例中仅1例有效。
  • 缓解见于PD-L1不表达者,IHC可捕获所有MMRD病例。

核心结论

  • Avelumab在MMRD子宫内膜癌中显示有前景的抗肿瘤活性,且不依赖PD-L1状态。
  • Avelumab在MMRP/非POLE突变子宫内膜癌中活性低。
  • 免疫组化评估MMR状态是有效的患者筛选工具。

研究设计与样本

  • II期研究,评估PD-L1抑制剂Avelumab在子宫内膜癌两个队列中的疗效。
  • MMRD/POLE队列定义为IHC显示一个或多个MMR蛋白表达缺失和/或POLE外切酶域突变。
  • MMRP队列定义为所有MMR蛋白IHC表达正常。
  • 共同主要终点为客观缓解(OR)和6个月无进展生存(PFS6)。
  • Avelumab 10 mg/kg静脉给药,每2周一次,直至进展或不可接受毒性。

主要发现

  • MMRD队列中无POLE突变肿瘤患者入组,MMRP队列中所有肿瘤均无POLE突变。
  • MMRP队列在第一阶段因无效关闭:16例中仅1例同时达到OR和PFS6。
  • MMRD队列在入组17例后达到预设主要终点(4例OR);15例启动Avelumab治疗的患者中,4例达OR(1例完全缓解,3例部分缓解;OR率26.7%,95%CI 7.8%-55.1%)。
  • 6例达PFS6(包括所有4例OR;PFS6率40.0%,95%CI 16.3%-66.7%),其中4例截至数据截止时仍在持续。

临床怎么用

  • 对于MMRD子宫内膜癌患者,可考虑使用Avelumab,且无需依赖PD-L1状态筛选。
  • 应采用免疫组化评估MMR状态以筛选可能从Avelumab获益的患者。
  • MMRP/非POLE突变子宫内膜癌患者不太可能从Avelumab单药中获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Despite the tissue-agnostic approval of pembrolizumab in mismatch repair deficient (MMRD) solid tumors, important unanswered questions remain about the role of immune checkpoint blockade in mismatch repair-proficient (MMRP) and -deficient endometrial cancer (EC). METHODS: This phase II study evaluated the PD-L1 inhibitor avelumab in two cohorts of patients with EC: (1) MMRD/POLE (polymerase ε) cohort, as defined by immunohistochemical (IHC) loss of expression of one or more mismatch repair (MMR) proteins and/or documented mutation in the exonuclease domain of POLE; and (2) MMRP cohort with normal IHC expression of all MMR proteins. Coprimary end points were objective response (OR) and progression-free survival at 6 months (PFS6). Avelumab 10 mg/kg intravenously was administered every 2 weeks until progression or unacceptable toxicity. RESULTS: Thirty-three patients were enrolled. No patient with POLE-mutated tumor was enrolled in the MMRD cohort, and all MMRP tumors were not POLE-mutated. The MMRP cohort was closed at the first stage because of futility: Only one of 16 patients exhibited both OR and PFS6 responses. The MMRD cohort met the predefined primary end point of four ORs after accrual of only 17 patients; of 15 patients who initiated avelumab, four exhibited OR (one complete response, three partial responses; OR rate, 26.7%; 95% CI, 7.8% to 55.1%) and six (including all four ORs) PFS6 responses (PFS6, 40.0%; 95% CI, 16.3% to 66.7%), four of which are ongoing as of data cutoff date. Responses were observed in the absence of PD-L1 expression. IHC captured all cases of MMRD subsequently determined by polymerase chain reaction or genomically via targeted sequencing. CONCLUSION: Avelumab exhibited promising activity in MMRD EC regardless of PD-L1 status. IHC for MMR assessment is a useful tool for patient selection. The activity of avelumab in MMRP/non-POLE-mutated ECs was low.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Konstantinopoulos PA, Luo W, Liu JF, et al. Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer. J Clin Oncol. 2019. PMID: 31461377. doi:10.1200/JCO.19.01021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。